Aplastic anemia secondary to adjuvant Osimertinib therapy: a case report and a review of literature
Aplastic anemia is a rare hematological disorder characterized by suppressed hematopoiesis and pancytopenia. Although several drugs have been associated with aplastic anemia, its occurrence in response to Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibit...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1275275/full |
| _version_ | 1797300287854084096 |
|---|---|
| author | Ahmed Abdalhadi Nabil E. Omar Nabil E. Omar Samah Kohla Samah Kohla Hassan Aakel Yeslem Ekeibed Reyad Mohsen |
| author_facet | Ahmed Abdalhadi Nabil E. Omar Nabil E. Omar Samah Kohla Samah Kohla Hassan Aakel Yeslem Ekeibed Reyad Mohsen |
| author_sort | Ahmed Abdalhadi |
| collection | DOAJ |
| description | Aplastic anemia is a rare hematological disorder characterized by suppressed hematopoiesis and pancytopenia. Although several drugs have been associated with aplastic anemia, its occurrence in response to Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is extremely rare. We present a case report of a 63-year-old patient with locally advanced non-small cell lung cancer (NSCLC) who developed aplastic anemia following adjuvant treatment with Osimertinib. Extensive investigations ruled out infectious etiology, and the absence of bone marrow involvement or other identifiable causes suggested a drug-induced etiology, specifically Osimertinib. This case report emphasizes the importance of recognizing this adverse event and considering it as a potential complication of Osimertinib therapy. Vigilant monitoring and prompt management are essential for optimizing patient outcomes. Further studies are needed to better understand the risk factors, underlying mechanisms, and management strategies for Osimertinib-induced aplastic anemia in the adjuvant settings. |
| first_indexed | 2024-03-07T23:05:04Z |
| format | Article |
| id | doaj.art-5fde40c25d04426bbe6ee36faf7de1b2 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-07T23:05:04Z |
| publishDate | 2024-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-5fde40c25d04426bbe6ee36faf7de1b22024-02-22T05:19:09ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-02-011410.3389/fonc.2024.12752751275275Aplastic anemia secondary to adjuvant Osimertinib therapy: a case report and a review of literatureAhmed Abdalhadi0Nabil E. Omar1Nabil E. Omar2Samah Kohla3Samah Kohla4Hassan Aakel5Yeslem Ekeibed6Reyad Mohsen7Medical Oncology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, QatarPharmacy Department, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, QatarHealth Sciences Program, Clinical and Population Health Research, College of Pharmacy, Qatar University, Doha, QatarLab Medicine and Pathology, Hematopathology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, QatarMedicine, Weill Cornell Medicine, Doha, QatarMedical Oncology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, QatarClinical Hematology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, QatarMedical Oncology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, QatarAplastic anemia is a rare hematological disorder characterized by suppressed hematopoiesis and pancytopenia. Although several drugs have been associated with aplastic anemia, its occurrence in response to Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is extremely rare. We present a case report of a 63-year-old patient with locally advanced non-small cell lung cancer (NSCLC) who developed aplastic anemia following adjuvant treatment with Osimertinib. Extensive investigations ruled out infectious etiology, and the absence of bone marrow involvement or other identifiable causes suggested a drug-induced etiology, specifically Osimertinib. This case report emphasizes the importance of recognizing this adverse event and considering it as a potential complication of Osimertinib therapy. Vigilant monitoring and prompt management are essential for optimizing patient outcomes. Further studies are needed to better understand the risk factors, underlying mechanisms, and management strategies for Osimertinib-induced aplastic anemia in the adjuvant settings.https://www.frontiersin.org/articles/10.3389/fonc.2024.1275275/fullEGFRTKISCLCAAlung adecarcinoma |
| spellingShingle | Ahmed Abdalhadi Nabil E. Omar Nabil E. Omar Samah Kohla Samah Kohla Hassan Aakel Yeslem Ekeibed Reyad Mohsen Aplastic anemia secondary to adjuvant Osimertinib therapy: a case report and a review of literature Frontiers in Oncology EGFR TKI SCLC AA lung adecarcinoma |
| title | Aplastic anemia secondary to adjuvant Osimertinib therapy: a case report and a review of literature |
| title_full | Aplastic anemia secondary to adjuvant Osimertinib therapy: a case report and a review of literature |
| title_fullStr | Aplastic anemia secondary to adjuvant Osimertinib therapy: a case report and a review of literature |
| title_full_unstemmed | Aplastic anemia secondary to adjuvant Osimertinib therapy: a case report and a review of literature |
| title_short | Aplastic anemia secondary to adjuvant Osimertinib therapy: a case report and a review of literature |
| title_sort | aplastic anemia secondary to adjuvant osimertinib therapy a case report and a review of literature |
| topic | EGFR TKI SCLC AA lung adecarcinoma |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1275275/full |
| work_keys_str_mv | AT ahmedabdalhadi aplasticanemiasecondarytoadjuvantosimertinibtherapyacasereportandareviewofliterature AT nabileomar aplasticanemiasecondarytoadjuvantosimertinibtherapyacasereportandareviewofliterature AT nabileomar aplasticanemiasecondarytoadjuvantosimertinibtherapyacasereportandareviewofliterature AT samahkohla aplasticanemiasecondarytoadjuvantosimertinibtherapyacasereportandareviewofliterature AT samahkohla aplasticanemiasecondarytoadjuvantosimertinibtherapyacasereportandareviewofliterature AT hassanaakel aplasticanemiasecondarytoadjuvantosimertinibtherapyacasereportandareviewofliterature AT yeslemekeibed aplasticanemiasecondarytoadjuvantosimertinibtherapyacasereportandareviewofliterature AT reyadmohsen aplasticanemiasecondarytoadjuvantosimertinibtherapyacasereportandareviewofliterature |